STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 6/Line 121-122	Abstract/Methods
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 6/Line 123-129;	Abstrcat/Methods and
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 8-9/Line 148-188	Main text/Introduction
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 9/Line 183-188	Main text/Introduction
Methods				
Study design	4	Present key elements of study design early in the paper	Page 9-10/Line 192-195	Methods/Design
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 10/Line 198-207	Methods/Patients
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 9-10/Line 193-195	Methods/Design
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	"N/A" is not a matched study	"N/A" is not a matched study
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 10/Line 205-207	Methods/Patients
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 10-12/Line 216-246	Methods/Antibody Measurements
Bias	9	Describe any efforts to address potential sources of bias	Page 12/Line 249-269	Methods /Statistical
Study size	10	Explain how the study size was arrived at	Page 12/Line 249-269	Methods /Statistical
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 12/Line 249-269	Methods /Statistical analysis

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 12/Line 249-269	Methods /Statistical
		(b) Describe any methods used to examine subgroups and interactions	Page 12/Line 249-269	Methods /Statistical
		(c) Explain how missing data were addressed	Page 12/Line 249-269	Methods /Statistical
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	Page 12/Line 249-269	Methods /Statistical
		(e) Describe any sensitivity analyses	Page 12/Line 249-269	Methods /Statistical
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 13/Line 266	Results/Characteristics of the evaluated patients
		(b) Give reasons for non-participation at each stage	"N/A"There is not	"N/A" There is not
		(c) Consider use of a flow diagram	"N/A" It is not neccesary	"N/A" It is nor neccesary
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 13/Line 266-270	Results/Characteristics of the evaluated patients
		(b) Indicate number of participants with missing data for each variable of interest	"N/A" No missing data	"N/A" No missing data
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	"N/A" No cohort study	"N/A" No cohort study
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	"N/A" No cohort study	"N/A" No cohort study
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	"N/A" No case-control	"N/A" No case-control
		Cross-sectional study—Report numbers of outcome events or summary measures	"N/A" No cross-sectional	"N/A" No cross-sectional
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 13-14/Line 273-274; 284-285; 292-296	Results/Seropositivity prevalence (IgG +);
		(b) Report category boundaries when continuous variables were categorized	Table 1	Table 1 - Age, median,
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	"N/A"	"N/A"
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	"N/A" No report other	"N/A" No report other
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 15-16/Line 317-322;	Discussion
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 16/Line 347-348	Discussion

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 17/Line 368-375	Conclusions
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 17/Line 368-375	Conclusions
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 19/Line 410-412	Acknowledgments

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article Information: https://dx.doi.org/10.21037/tlcr-21-504
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.